Vericel (VCEL) Long-Term Debt Issuances (2013 - 2017)
Vericel's (VCEL) quarterly Long-Term Debt Issuances came in at $14.8 million in Q4 2017, up 243.23% year-over-year from $4.3 million in Q4 2016, and up 74065.0% quarter-over-quarter from -$20000.0 in Q3 2017.
Analysis
Vericel (VCEL) Long-Term Debt Issuances (2013 - 2017) Analysis & Trends
Vericel has disclosed Long-Term Debt Issuances across 5 years of filings, most recently posting $14.8 million for Q4 2017.
- In Q4 2017, Long-Term Debt Issuances rose 243.23% year-over-year to $14.8 million; the TTM figure through Dec 2017 stood at $14.8 million (up 16.39% YoY), while the FY2018 annual figure was $17.5 million, up 18.52% from the prior year.
- Long-Term Debt Issuances came in at $14.8 million for Q4 2017 at Vericel, up from -$20000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $14.8 million in Q4 2017 to a low of -$20000.0 in Q3 2017.
- Average Long-Term Debt Issuances over 5 years is $2.0 million, with a median of $9000.0 recorded in 2015.
- Year-over-year, Long-Term Debt Issuances jumped 66566.67% in 2016 and plunged 100.33% in 2017.
- Over 5 years, Long-Term Debt Issuances stood at $4000.0 in 2013, then surged by 62300.0% to $2.5 million in 2014, then slumped by 99.64% to $9000.0 in 2015, then jumped by 47788.89% to $4.3 million in 2016, then soared by 243.23% to $14.8 million in 2017.
- Per Business Quant data, the three most recent Long-Term Debt Issuances figures were $14.8 million in Q4 2017, -$20000.0 in Q3 2017, and $10000.0 in Q2 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | 14.79 Mn |
| Sep 30, 2017 | -20,000.00 |
| Jun 30, 2017 | 10,000.00 |
| Mar 31, 2017 | 10,000.00 |
| Dec 31, 2016 | 4.31 Mn |
| Sep 30, 2016 | 6.00 Mn |
| Jun 30, 2016 | 2.39 Mn |
| Mar 31, 2016 | 9,000.00 |
| Dec 31, 2015 | 9,000.00 |
| Sep 30, 2015 | 9,000.00 |
| Jun 30, 2015 | 8,000.00 |
| Mar 31, 2015 | 9,000.00 |
| Jun 30, 2014 | 2.50 Mn |
| Mar 31, 2014 | 4,000.00 |
| Dec 31, 2013 | 4,000.00 |